Back to discover

Protein / target

BDNF/NT-3 growth factors receptor

Encoded byNTRK2Q16620Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
6
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Brain-derived neurotrophic factor receptor

Strongest disease association

Obesity, hyperphagia, and developmental delay

Via encoding gene NTRK2 · Genetic evidence · score 0.83

Therapeutic position

Established drug target

Small molecules

Research activity

Emerging research

18 papers · latest 2025

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity.

View complete UniProt function annotation

Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity (By similarity). Receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2 (PubMed:15494731, PubMed:7574684). Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation (PubMed:15494731). Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades. Through SHC1, FRS2, SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for instance neuronal differentiation including neurite outgrowth. Through the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade that mainly regulates growth and survival. Through PLCG1 and the downstream protein kinase C-regulated pathways controls synaptic plasticity. Thereby, plays a role in learning and memory by regulating both short term synaptic function and long-term potentiation. PLCG1 also leads to NF-Kappa-B activation and the transcription of genes involved in cell survival. Hence, it is able to suppress anoikis, the apoptosis resulting from loss of cell-matrix interactions. May also play a role in neutrophin-dependent calcium signaling in glial cells and mediate communication between neurons and glia

Subcellular location

Cell membraneEndosome membraneEarly endosome membraneCell projection, axonCell projection, dendriteCytoplasm, perinuclear regionPostsynaptic density
Domains and Gene Ontology detail (47)

Domains & features

LRRNTLRRCTIg-like C2-type 1Ig-like C2-type 2Protein kinase

Gene Ontology

  • Caxon
  • Caxon terminus
  • Ccytosol
  • Cdendrite
  • Cdendritic spine
  • Cearly endosome
  • Cearly endosome membrane
  • Cperinuclear region of cytoplasm
  • Cplasma membrane
  • Cpostsynaptic density
  • Creceptor complex
  • Cterminal bouton

822 aa · 92 kDa · 7 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalUniProt · GO · ReactomeSynaptic signallingUniProt · GOReceptor tyrosine kinase signallingUniProt · GOOncogenic signallingReactomeTranscriptional regulationUniProt · GO
View supporting evidence

Cell proliferation & survival

  • ·Receptor tyrosine kinase involved in the development and the maturation of the central a…
  • ·positive regulation of cell population proliferation
  • ·PIP3 activates AKT signaling
  • ·PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling

Synaptic signalling

  • ·Receptor tyrosine kinase involved in the development and the maturation of the central a…
  • ·Postsynaptic density
  • ·postsynaptic density
  • ·trans-synaptic signaling by BDNF, modulating synaptic transmission

Receptor tyrosine kinase signalling

  • ·Receptor tyrosine kinase involved in the development and the maturation of the central a…
  • ·cell surface receptor protein tyrosine kinase signaling pathway

Oncogenic signalling

  • ·Constitutive Signaling by Aberrant PI3K in Cancer

Transcriptional regulation

  • ·Receptor tyrosine kinase involved in the development and the maturation of the central a…
  • ·positive regulation of gene expression
View underlying pathways (14)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

NTF3NTF4SHC1NGFBDNFGDNFSHC3PLCG1FRS2NGFRNTRK2

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

3 medicines · 2 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Carcinoma, Non-Small-Cell Lung1 medicine

6 medicines meet Open Targets' target-level approved-medicine definition; the 3 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

3

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

repotrectinib
ApprovedInhibitor

Neurotrophic tyrosine kinase receptor type 2 inhibitor

Indicated for Neoplasms

Direct interaction with this protein · 1 of 6 recorded protein targets

larotrectinib
ApprovedInhibitor

Neurotrophic tyrosine kinase receptor inhibitor

Indicated for Neoplasms

Acts on a complex — shared with NTRK1, NTRK3 · 1 of 3 recorded protein targets — narrow recorded profile

entrectinib
ApprovedInhibitor

Neurotrophic tyrosine kinase receptor inhibitor

Indicated for Carcinoma, Non-Small-Cell Lung, Neoplasms

Acts on a complex — shared with NTRK1, NTRK3 · 1 of 5 recorded protein targets

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene NTRK2

Gene-level evidence surfaced through the gene NTRK2that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Neoplasms
0.88Well supported

Clinical evidence dominant · Open Targets 0.63

Obesity, hyperphagia, and developmental delay
0.85Well supported

Genetic evidence dominant · Open Targets 0.71

Genetic developmental and epileptic encephalopathy
0.83Well supported

Genetic evidence dominant · Open Targets 0.61

Carcinoma, Non-Small-Cell Lung
0.82Well supported

Clinical evidence dominant · Open Targets 0.65

Undetermined early-onset epileptic encephalopathy
0.67Moderately supported

Genetic evidence dominant · Open Targets 0.38

View evidence synthesis (5)
NeoplasmsWell supported
0.88
agreement 0.790.97
Clinical43%Somatic mutation19%Pathway16%Genetic13%Literature9%

Open Targets aggregate 0.63 · 5 independent evidence families

Obesity, hyperphagia, and developmental delayWell supported
0.85
agreement 0.730.97
Genetic88%Animal model11%Literature1%Genetic literaturedup

Open Targets aggregate 0.71 · 3 independent evidence families · 1 not counted as duplicate

Genetic developmental and epileptic encephalopathyWell supported
0.83
agreement 0.710.95
Genetic81%Animal model19%Literature0%Genetic literaturedup

Open Targets aggregate 0.61 · 3 independent evidence families · 1 not counted as duplicate

Carcinoma, Non-Small-Cell LungWell supported
0.82
agreement 0.710.93
Clinical64%Somatic mutation27%Literature9%RNA expression1%

Open Targets aggregate 0.65 · 4 independent evidence families

Undetermined early-onset epileptic encephalopathyModerately supported
0.67
agreement 0.550.79
Genetic79%Animal model21%

Open Targets aggregate 0.38 · 2 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Obesity, hyperphagia, and developmental delay0.71
Carcinoma, Non-Small-Cell Lung0.65
Neoplasms0.63
Genetic developmental and epileptic encephalopathy0.61
Neurodegenerative Diseases0.50
Undetermined early-onset epileptic encephalopathy0.38
Infantile spasms0.38
Carcinoma, Pancreatic Ductal0.38

Drug development

13 compounds recorded · 6 approved · 7 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 3 drugs that target this protein in Forefront's canonical graph (3 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (10)
LESTAURTINIBApproval
LAROTRECTINIB SULFATEApproval
CEP-2563Phase 1
LAROTRECTINIBApproval
CENEGERMINApproval
ENTRECTINIBApproval
REPOTRECTINIBApproval
ALTIRATINIBPhase 1
AZD-6918Phase 1
TALETRECTINIBPhase 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (literature and uniprot ubiquitination) — no clinical-stage drug of this modality recorded.

Other modalitiesStrong

Approved Drug support this modality.

View underlying tractability evidence (14)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMMAB · Human Protein Atlas locPR · LiteraturePR · UniProt UbiquitinationPR · Half-life DataPR · Small Molecule BinderOC · Approved Drug

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

suicidal thoughtsClinPGx

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

ACTIVE_NOT_RECRUITING · via entrectinib · NCT03994796

ACTIVE_NOT_RECRUITING · via larotrectinib · NCT02465060

ClinicalTrials.gov via the drug-target graph.

What's happening now

4

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 3 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2025-01-13

    Approval: Augtyro (EMA)

    ema · regulatory · ema · via repotrectinib

  2. New publication2024-01-01
    Repotrectinib in <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung Cancer.

    The New England journal of medicine · 2024 · 168 citations · Europe PMC · via repotrectinib

  3. Regulatory approval2020-07-31

    Approval: Rozlytrek (EMA)

    ema · regulatory · ema · via entrectinib

  4. New publication2018-02-01
    Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

    The New England journal of medicine · 2018 · 1,987 citations · Europe PMC · via larotrectinib

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.

Research activity

18 papers · to 2025

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Kowiański P · Cellular and molecular neurobiology · 2018

Lu B · Learning & memory (Cold Spring Harbor, N.Y.) · 2003

Saarelainen T · The Journal of neuroscience : the official journal of the Society for Neuroscience · 2003

Recent

Targeted rescue of synaptic plasticity improves cognitive decline in sepsis-associated encephalopathy.

Grünewald B · Molecular therapy : the journal of the American Society of Gene Therapy · 2024

Vagus Nerve Stimulation (VNS) Modulates Synaptic Plasticity in the Infralimbic Cortex via Trk-B Receptor Activation to Reduce Drug-Seeking in Male Rats.

Driskill CM · The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024

Europe PMC papers linked directly to this protein.